By Catherine Eckford2025-12-09T11:21:58
The US approval for the Ayrmid company’s novel transplant option Omisirge adds to its existing licence in haematological malignancy.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-23T15:25:00Z
2026-06-22T13:25:00Z
Sponsored by IMA Pharma
2026-06-16T10:59:00Z
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2025-10-08T07:00:00
Sponsored by Entegris
2025-12-11T13:32:00
Sponsored by Hexagon
2026-06-22T13:25:00
Sponsored by IMA Pharma
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
Site powered by Webvision Cloud